Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL20984137 | 0.98 | KMT2A (0.56) | KMT2AMEN1ALDH1A1TP53LMNA | |
| Hydrochloric Acid SCHEMBL966892 | 0.98 | KMT2A (0.56) | KMT2AMEN1ALDH1A1TP53LMNA | |
| Phosphoric Acid SCHEMBL28373371 | 0.90 | KMT2A (0.56) | KMT2AMEN1ALDH1A1TP53POLB | |
| Sulfuric Acid SCHEMBL20984443 | 0.90 | KMT2A (0.56) | KMT2AMEN1ALDH1A1TP53LMNA | |
| Oxalic Acid SCHEMBL28378021 | 0.90 | KMT2A (0.60) | KMT2AMEN1ALDH1A1LMNAPOLB | |
| Nitric Acid SCHEMBL28380031 | 0.87 | MEN1 (0.54) | KMT2AMEN1ALDH1A1TP53LMNA | |
| SCHEMBL11816896 | 0.84 | TRPV4 (0.46) | KMT2AMEN1ALDH1A1TP53LMNA | |
| SCHEMBL23565733 | 0.83 | KMT2A (0.61) | KMT2AMEN1ALDH1A1TP53LMNA | |
| SCHEMBL8329121 | 0.83 | KMT2A (0.61) | KMT2AMEN1ALDH1A1TP53LMNA | |
| Hydrochloric Acid SCHEMBL20984711 | 0.82 | LPAR1 (0.44) | KMT2AMEN1ALDH1A1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10442777-B2 | Use of substituted oxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2019-10-15 | — | — | US | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20190016694-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2019-01-17 | — | — | US | disclosed |
| EP-3112350-B1 | METHOD FOR PRODUCING PYRAZOLE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-7642358-B2 | Substituted phenylacetic acids | METABOLEX, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-0915856-A4 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6613786-B2 | Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | HEWAWASAM PIYASENA (US) | 2003-07-31 | — | — | US | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0915856-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | Bristol-Myers Squibb Company (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998004135-A1 | DIPHENYL HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-02-05 | — | — | WO | disclosed |
| US-3987234-A | ACRYLIC ESTER POLYMERS | HENKEL & CIE G.M.B.H. (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016694-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | KMT2A 4011/4885MEN1 2850/4885ALDH1A1 1574/4885 |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | KMT2A 4698/4885MEN1 2006/4885ALDH1A1 2893/4885 |
| US-10442777-B2 | Use of substituted oxadiazoles for combating phytopathogenic fungi | CYP51A1, DPM1, NOX1 | KMT2A 4011/4885MEN1 2850/4885ALDH1A1 1574/4885 |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | PDE3A, ADRB2, ADRB3 | KMT2A 981/4885MEN1 3259/4885ALDH1A1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.